The hallmark of Parkinson’s disease is a misfolded protein in the body, called alpha-synuclein, that is implicated in the loss of dopamine neurons in the brain. When those dopamine neurons are lost, ...

Nilotinib, a blood cancer medicine, was previously shown to improve movement and mental function in a small group of patients ...

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet ...

Neurodegenerative diseases of aging like Parkinson's disease (PD) or Alzheimer's disease (AD) are usually not diagnosed until ...

The findings align with an earlier study that showed possible disease-modifying effects of nilotinib ... this pathway and ...

Researchers have identified unique RNA structures called G-quadruplexes (G4s) that promote harmful α-synuclein protein ...

Brain disorders like Parkinson's or Alzheimer's Disease start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early stages could slow or ...

Researchers have developed a method to analyze extracellular vesicles (EVs) in blood for early detection of Parkinson’s ...

A million Americans have Parkinson’s disease, and that number is expected to increase to 1.2 million by 2030. Most of those afflicted are between 75 and 85, but 4% are under 50. The cause is still ...

Nilotinib (Tasigna) — a drug for myeloid leukemia — improved biomarkers and cognitive outcomes in study participants with dementia with Lewy bodies, a new study finds.

About 7 million Americans live with chronic neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral ...